What are the survival benefits of adding durvalumab to chemotherapy for muscle-invasive bladder cancer?
For muscle-invasive bladder cancer (MIBC), the standard treatment has been cisplatin-based chemotherapy before surgery (neoadjuvant) followed by radical cystectomy. A recent phase 3 trial called NIAGARA tested whether adding the immunotherapy drug durvalumab (Imfinzi) to chemotherapy, both before and after surgery, could improve outcomes. The answer is yes: the combination significantly improved event-free survival and overall survival compared to chemotherapy alone 478.
What the research says
The NIAGARA trial randomly assigned 1,063 patients with MIBC to receive either durvalumab plus gemcitabine and cisplatin before surgery, followed by durvalumab alone after surgery, or chemotherapy alone before surgery with no additional treatment afterward 4. The results showed that adding durvalumab reduced the risk of disease progression, recurrence, or death by 32% (hazard ratio 0.68) for event-free survival 48. The median event-free survival was not reached in the durvalumab group, compared to 46.1 months in the chemotherapy-only group 4.
Overall survival also improved with durvalumab. The hazard ratio for death was 0.75, meaning a 25% reduction in the risk of death 8. A cost-effectiveness analysis based on the NIAGARA trial found that adding durvalumab provided an additional 0.68 quality-adjusted life years (QALYs) at an incremental cost of about $86,485, with an incremental cost-effectiveness ratio of $93,694 per QALY, which is considered cost-effective in the U.S. 7.
It is important to note that the NIAGARA trial included only patients who were eligible for cisplatin-based chemotherapy 4. For patients who cannot take cisplatin, other immunotherapy combinations are being studied, such as enfortumab vedotin plus pembrolizumab, which also showed improved event-free survival compared to surgery alone 2. The FDA approved durvalumab with chemotherapy for this indication in March 2025 4.
What to ask your doctor
- Am I eligible for cisplatin-based chemotherapy, and would adding durvalumab be appropriate for my case?
- What are the potential side effects of durvalumab plus chemotherapy, and how do they compare to chemotherapy alone?
- How does the NIAGARA trial evidence apply to my specific stage and type of bladder cancer?
- Are there any ongoing clinical trials testing other immunotherapy combinations for MIBC that I might consider?
- What is the recommended schedule for durvalumab treatment before and after surgery?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.